Jason Harris

Dr. Harris is vice president, head of chemistry at Autobahn Therapeutics.

Dr. Harris has a proven track record of discovering high-quality small molecule therapies with chemistry experience ranging from hit generation through solid oral dosage development. Prior to Autobahn, Dr. Harris was head of chemistry and CMC at Kalika Biosciences, a venture capital-backed discovery engine focused on inflammation and innate immunity. During his tenure with Kalika, he contributed to the discovery of two clinical candidates and several development candidates. He also served as a senior member of the scientific teams at Ignyta, Exelixis, and Global Blood Therapeutics, where he contributed to the discovery of the approved therapy OxbrytaTM. He received his Ph.D. in organic chemistry from University of California, Irvine, and a B.S. in chemistry from Stony Brook University.